Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation

Jennifer Mersereau; Mary Anne Dooley

doi:10.1016/j.rdc.2009.12.010

Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation

Rheum Dis Clin North Am. 2010 Feb;36(1):99-108, viii. doi: 10.1016/j.rdc.2009.12.010.

Authors

Jennifer Mersereau¹, Mary Anne Dooley

Affiliation

¹ Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of North Carolina at Chapel Hill, CB #7570, 4001 Old Clinic Building, Chapel Hill, NC 27599-7570, USA.

PMID: 20202593
DOI: 10.1016/j.rdc.2009.12.010

Abstract

Intravenous cyclophosphamide remains an important therapy for patients with severe systemic lupus erythematosus--including lupus nephritis, which primarily affects women in their reproductive years. As prognosis improves, the chronic toxicity of this therapy assumes greater importance. This article reviews cyclophosphamide use, its effect on gonadal function, and protection of gonadal reserve during therapy. Egg, embryo, or gonadal tissue cryopreservation and alternative therapeutic strategies are considered.

MeSH terms

Adult
Animals
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects*
Female
Gonadotropin-Releasing Hormone / agonists
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects*
Infertility, Female / chemically induced
Infertility, Female / prevention & control
Infertility, Male / chemically induced
Infertility, Male / prevention & control
Infusions, Intravenous
Lupus Nephritis / drug therapy*
Male
Ovary / drug effects*
Primary Ovarian Insufficiency / chemically induced
Primary Ovarian Insufficiency / prevention & control
Rats
Reproductive Techniques, Assisted
Spermatozoa / drug effects*
Young Adult

Substances

Immunosuppressive Agents
Gonadotropin-Releasing Hormone
Cyclophosphamide